Literature DB >> 16042233

A review of stress-relapse interactions in multiple sclerosis: important features and stress-mediating and -moderating variables.

R F Brown1, C C Tennant, S M Dunn, J D Pollard.   

Abstract

Studies do not provide a consensus opinion of the relationship between stress and relapse in relapsing-remitting multiple sclerosis (RRMS). Few studies have defined the critical features of these stressful situations, or examined the role of stress-mediating and -moderating variables. Available evidence indicates that the relationship between life stress and relapse is complex, and is likely to depend on factors such as stressor chronicity, frequency, severity and type, and individual patient characteristics such as depression, health locus of control and coping strategy use. Little is known about how these factors, individually or in combination, are related to MS disease activity. Viral infections are also likely to precipitate relapse in MS, and significant life-stress may further enhance this relationship. The nature and strength of these interrelationships have strong clinical implications. MS patients are particularly vulnerable to a deteriorating cycle of stressful life events, illness episodes and disability. Timely multidisciplinary care interventions aimed at both minimizing psychological distress and physical symptoms may halt this downward reciprocal cycle. Little is known of the pathogenesis of these putative stress-induced changes in disease activity, and almost all stressor studies suffer from some biases or limitations.

Entities:  

Mesh:

Year:  2005        PMID: 16042233     DOI: 10.1191/1352458505ms1170oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  8 in total

1.  Predictors of Mood Disorders in Parents With Multiple Sclerosis: The Role of Disability Level, Coping Techniques, and Perceived Social Support.

Authors:  Jessica Podda; Michele Messmer Uccelli; Andrea Tacchino; Ludovico Pedullà; Margherita Monti Bragadin; Mario Alberto Battaglia; Giampaolo Brichetto; Michela Ponzio
Journal:  Int J MS Care       Date:  2022-06-20

2.  Relationship between psychosocial factors and onset of multiple sclerosis.

Authors:  X J Liu; H X Ye; W P Li; R Dai; D Chen; M Jin
Journal:  Eur Neurol       Date:  2009-07-01       Impact factor: 1.710

3.  Social disruption alters pain and cognition in an animal model of multiple sclerosis.

Authors:  H R Linsenbardt; J L Cook; E E Young; E G Vichaya; C R Young; N M Reusser; R Storts; C J Welsh; M W Meagher
Journal:  J Neuroimmunol       Date:  2015-09-12       Impact factor: 3.478

4.  Psychometric Properties of the HADS Measure of Anxiety and Depression Among Multiple Sclerosis Patients in Croatia.

Authors:  Ana Jerković; Ana Proroković; Meri Matijaca; Jelena Vuko; Ana Poljičanin; Angela Mastelić; Ana Ćurković Katić; Vana Košta; Lea Kustura; Krešimir Dolić; Zoran Ðogaš; Maja Rogić Vidaković
Journal:  Front Psychol       Date:  2021-11-30

5.  The Gap in the Current Research on the Link between Health Locus of Control and Multiple Sclerosis: Lessons and Insights from a Systematic Review.

Authors:  Nicola Luigi Bragazzi
Journal:  Mult Scler Int       Date:  2013-02-14

Review 6.  Meditation as an adjunct to the management of multiple sclerosis.

Authors:  Adam B Levin; Emily J Hadgkiss; Tracey J Weiland; George A Jelinek
Journal:  Neurol Res Int       Date:  2014-07-01

Review 7.  Antidepressants on Multiple Sclerosis: A Review of In Vitro and In Vivo Models.

Authors:  Eleni Stamoula; Spyridon Siafis; Ioannis Dardalas; Alexandra Ainatzoglou; Alkis Matsas; Theodoros Athanasiadis; Chrysanthi Sardeli; Konstantinos Stamoulas; Georgios Papazisis
Journal:  Front Immunol       Date:  2021-05-20       Impact factor: 7.561

8.  The Role of Stress Perception and Coping with Stress and the Quality of Life Among Multiple Sclerosis Patients.

Authors:  Aleksandra Kołtuniuk; Magdalena Kazimierska-Zając; Kinga Cisek; Justyna Chojdak-Łukasiewicz
Journal:  Psychol Res Behav Manag       Date:  2021-06-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.